Average Co-Inventor Count = 4.64
ph-index = 14
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Xencor, Inc. (98 from 216 patents)
2. Allergan, Inc. (3 from 2,285 patents)
3. Genentech, Inc. (1 from 3,221 patents)
4. Amgen Inc. (1,973 patents)
100 patents:
1. 12448423 - Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains
2. 12415849 - Heterodimeric proteins
3. 12398207 - Heterodimeric antibodies that bind CD3 and CLDN6
4. 12378313 - Bispecific binding agents binding to CLDN18.2 and CD3
5. 12359002 - Heterodimeric antibodies that bind CD3 and tumor antigens
6. 12239688 - IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereof
7. 12234270 - IL-12 heterodimeric Fc-fusion proteins
8. 12152076 - Bispecific and monospecific antibodies using novel anti-PD-1 sequences
9. 12139525 - Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
10. 12129309 - Heterodimeric antibodies that bind CD3 and CD38
11. 12006345 - Untargeted and targeted IL-10 Fc-fusion proteins
12. 11981717 - Engineered IL-2 Fc fusion proteins
13. 11945880 - Heterodimeric antibodies that bind CD3 and tumor antigens
14. 11932675 - PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
15. 11859012 - Heterodimeric antibodies that bind CD3 and GPC3